FDA Approves Merck’s Idvynso: A New Alternative for HIV Patients Switching from Biktarvy In a move that reshapes the competitive landscape of antiretroviral therapy, the U.S. Food and Drug Administration has granted a FDA nod for Merck’s HIV drug Idvynso. This approval provides a vital new lifeline for patients who have struggled with existing treatments. … Read more
Merck’s $6.7 Billion Terns Pharma Deal: A Strategic Move Against Novartis’s Cancer Dominance In a significant pharmaceutical maneuver, Merck has announced the acquisition of Terns Pharmaceuticals for $6.7 billion. This strategic investment is widely viewed as a proactive step to bolster Merck’s pipeline and mitigate potential revenue losses as its blockbuster cancer drug, Keytruda, faces … Read more
Just 13% of Americans report having “a great deal” of confidence in the CDC, according to a recent Gallup poll – a historic low. This erosion of trust, combined with recent changes to the recommended childhood vaccine schedule, isn’t merely a policy shift; it’s a harbinger of a potentially fractured future for public health, one … Read more